Biopharma & Life Sciences
Coherus Oncology Executive Compensation (FY25)
CHRS · Executive and director compensation, fiscal 2024 to 2025
Data as of September 7, 2026Latest filing (8-K): June 1, 2026
129 figures on this page: 127 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
Dennis Lanfear, President, Chief Executive Officer and Chairman of the Board of Directors, received $2,736,874 in total compensation for fiscal 2025, and compared with the $4,802,309 reported for fiscal 2024, Lanfear's total was 43.0% lower. The say-on-pay proposal drew 87.1% of votes cast for or against in favor at the meeting held May 27, 2026 for fiscal 2025. The disclosed peer group includes ACADIA Pharmaceuticals, Agenus, Agios Pharmaceuticals, Amicus Pharmaceuticals and Collegium Pharmaceuticals, among others. The new peer group (2026 compensation decisions) names Actuate Therapeutics, Allogene Therapeutics, Black Diamond Therapeutics, Cardiff Oncology and Caribou Biosciences, among others.
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Dennis Lanfear: $4,802,309 → $2,736,874 (43.0% lower)
Say-on-pay support: 54.3% → 87.1% (32.8 points higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Coherus Oncology's chief executive and what were they paid?
Dennis Lanfear, President, Chief Executive Officer and Chairman of the Board of Directors, received $2,736,874 in total compensation for fiscal 2025. Compared with the $4,802,309 reported for fiscal 2024, Lanfear's total was 43.0% lower.
What was Coherus Oncology's say-on-pay result?
The say-on-pay proposal drew 87.1% of votes cast for or against in favor at the meeting held May 27, 2026 for fiscal 2025.
Which companies are in Coherus Oncology's peer group?
The disclosed peer group includes ACADIA Pharmaceuticals, Agenus, Agios Pharmaceuticals, Amicus Pharmaceuticals and Collegium Pharmaceuticals, among others. The new peer group (2026 compensation decisions) names Actuate Therapeutics, Allogene Therapeutics, Black Diamond Therapeutics, Cardiff Oncology and Caribou Biosciences, among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Dennis Lanfear President, Chief Executive Officer and Chairman of the Board of Directors | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Paul Reider Former Chief Commercial Officer | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Bryan McMichael Chief Financial Officer | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Dennis Lanfear President, Chief Executive Officer and Chairman of the Board of Directors | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Paul Reider Former Chief Commercial Officer Departed during or after this year | ◇ | — | — | ◇ | — | — | ◇ | ◇ |
Bryan McMichael Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Bryan McMichael | OPTION | — | — | — | — | — | — | ◇ |
| Dennis Lanfear | OPTION | — | — | — | — | — | — | ◇ |
| Paul Reider | OPTION | — | — | — | — | — | — | ◇ |
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Bryan McMichael | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 8/7/2034 | |
| Option | ◇ | — | ◇ | 1/7/2032 | |
| Option | ◇ | — | ◇ | 1/4/2033 | |
| Option | ◇ | — | ◇ | 3/27/2033 | |
| Option | ◇ | — | ◇ | 1/2/2034 | |
| Option | ◇ | — | ◇ | 5/7/2035 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/3/2035 | |
| Option | ◇ | — | ◇ | 9/7/2032 | |
| Dennis Lanfear | Option | ◇ | — | ◇ | 1/4/2032 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/10/2035 | |
| Option | ◇ | — | ◇ | 1/5/2033 | |
| Option | ◇ | — | ◇ | 5/7/2035 | |
| SAR | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | 1/5/2034 | |
| Paul Reider | Option | ◇ | — | ◇ | 1/4/2032 |
| Option | ◇ | — | ◇ | 1/2/2034 | |
| Option | ◇ | — | ◇ | 1/3/2035 | |
| SAR | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/4/2033 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Mats L. Wahlström Lead independent director | ◇ | — | ◇ | — | — | — | ◇ |
Charles W. Newton | ◇ | — | ◇ | — | — | — | ◇ |
Ali J. Satvat | ◇ | — | ◇ | — | — | — | ◇ |
Rita A. Karachun | ◇ | — | ◇ | — | — | — | ◇ |
Georgia Erbez | ◇ | — | ◇ | — | — | — | ◇ |
Michael Ryan | ◇ | — | ◇ | — | — | — | ◇ |
Lee N. Newcomer, MD | ◇ | — | ◇ | — | — | — | ◇ |
Jill O'Donnell-Tormey, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Mark D. Stolper | ◇ | — | — | — | — | — | ◇ |
Dennis M. Lanfear served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- ACADIA Pharmaceuticals ACAD
- Agenus AGEN
- Agios Pharmaceuticals AGIO
- Amicus Pharmaceuticals FOLD
- Collegium Pharmaceuticals COLL
- Corcept Therapeutics CORT
- Deciphera Pharmaceuticals DCPH
- Dynavax Technologies DVAX
- Eagle Pharmaceuticals EGRX
- Fibrogen symbol not shown
- Heron Therapeutics HRTX
- Intercept Pharmaceuticals ICPT
- Ironwood Pharmaceuticals IRWD
- Karyopharm Therapeutics KPTI
- Mirum Pharmaceuticals MIRM
- Nektar Therapeutics NKTR
- Pacira BioSciences PCRX
- PTC Therapeutics PTCT
- Puma Biotechnology PBYI
- Supernus Pharmaceuticals SUPN
- Vanda Pharmaceuticals VNDA
new peer group (2026 compensation decisions)
- Actuate Therapeutics ACTU
- Allogene Therapeutics ALLO
- Black Diamond Therapeutics BDTX
- Cardiff Oncology CRDF
- Caribou Biosciences CRBU
- Corbus Pharmaceuticals CRBP
- Cullinan Therapeutics CGEM
- Lyell Immunopharma LYEL
- Olema Pharmaceuticals OLMA
- Perspective Therapeutics CATX
- Pliant Therapeutics PLRX
- Precigen PGEN
- RAPT Therapeutics RAPT
- Replimune Group REPL
- Xencor XNCR
- Zentalis Pharmaceuticals ZNTL
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 27, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 11, 2025 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Coherus Oncology disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Coherus Oncology sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
129 figures on this page: 127 cited to the filing that reported them, 2 calculated from figures it prints.
127 cited to the filing
2 calculated from the filing
Documents cited
- 0001104659-26-068615
- 0001558370-25-005825Summary Compensation Table
- 0001104659-26-045251Director Compensation Table · Outstanding Equity Awards at 2025 Fiscal Year End · Summary Compensation Table
- 0001104659-25-059351
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Coherus Oncology executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/CHRS (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Coherus Oncology and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Coherus Oncology discloses
The companies named in CHRS's own disclosed peer group.
ACADIA PharmaceuticalsAgios PharmaceuticalsAmicus PharmaceuticalsHeron TherapeuticsIronwood PharmaceuticalsMirum PharmaceuticalsPTC TherapeuticsSupernus PharmaceuticalsVanda PharmaceuticalsAllogene TherapeuticsCaribou BiosciencesLyell ImmunopharmaPliant TherapeuticsReplimune GroupXencorZentalis Pharmaceuticals
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}